BCLI Brainstorm Cell Therapeutics Inc.
USHealthcareAs of 2026-07-10 15:58
Why BCLI matters now
Brainstorm Cell Therapeutics Inc. (BCLI) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.08 with +0.93% on the session and $11.9M in market capitalization; recent performance reads 1-month +20.38% and YTD +56.36%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-2.1M, and EPS of $-0.19. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -70.2%.
The latest indexable market news headline is "BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $—; recent insider activity includes Pitts Peter Joe filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.86
P/S
0.00
EV/EBITDA
-1.26
DCF Value
$-0.73
FCF Yield
-70.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
109.2%
ROA
-1676.0%
ROIC
91.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-2.1M | $-0.19 |
| Q4 2025 | $0.00 | $-2.4M | $-0.22 |
| FY 2025 | $0.00 | $-10.3M | $-1.11 |
| Q3 2025 | $0.00 | $-2.1M | $-0.19 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.28
Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are specifically designed to address neurodegenerative diseases. At the heart of its strategy is the proprietary NurOwn cell therapy platform. This platform employs sophisticated cell culture techniques to prompt mesenchymal stem cells, derived from the patient's own bone marrow, to produce high concentrations of neurotrophic factors. This process aims to regulate neuroinflammatory and neurodegenerative disease mechanisms, bolster the survival of neurons, and ultimately enhance neurological function. NurOwn is currently undergoing significant clinical development, having completed a Phase III clinical trial for Amyotrophic Lateral Sclerosis (ALS). Additionally, it has successfully advanced through Phase II clinical trials for both progressive multiple sclerosis and Alzheimer's disease, with potential applications being explored for other neurodegenerative conditions. To support its therapeutic pipeline, the company has established a manufacturing partnership with Catalent for NurOwn. Incorporated in 2000, the company initially operated as Golden Hand Resources Inc. before adopting the name Brainstorm Cell Therapeutics Inc. in November 2004. Its corporate headquarters are situated in New York, New York.